



OESOPHAGEAL CANCER (OC)

GLOBAL CLINICAL TRIAL LANDSCAPE (2024)

#DYK
Did you know?

Globally, OC accounted for nearly **511,000 new cases in 2022**




Globally, **Oeso-phageal Cancer** is the **11th most diagnosed cancer** and the **7th most leading cause of cancer mortality**

Asia had the **highest incidence cases** and accounted for **nearly 70%** of the global incidence cases of OC

Europe had the **second highest incidence**, with over **53,500 cases**


North America had **more than 21,800 cases**, followed by rest of the world (ROW)

TRIAL CONTRIBUTIONS



Countries like **Mainland China**, the **United States**, **South Korea**, and **Spain** emerged as **top locations** for conducting trials

Asia-Pacific showed **faster recruitment durations** and **patient recruitment rates**



The **OC treatment market** offers diverse products by companies including **Advanz Pharma Corp. Ltd**, **BeiGene Ltd.**, **InnoKeys Pte. Ltd.** and **Simcere Pharmaceutical Group Ltd**



Multiple ongoing **Phase III trials** demonstrate continued efforts to enhance **OC treatment through antibody, small molecule, bispecific or multispecific antibody and peptide vaccine therapies**